

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2629.1003-009APPLICATION NO.
10/731,522SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONFIRST NAMED INVENTOR
Sudhir V. ShahFILING DATE
December 9, 2003

November 16, 2004

EXAMINER
Randall O. WinstonCONFIRMATION NO.
3719GROUP
1654

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
W	AJ	US 2003/0064929 A1	04/03/2003	Duranton <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
W	AL2	WO 90/04584	05/03/1990	BIOREX KUTATO FEJLESZTO KFT.		

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED

**SUPPLEMENTAL INFORMATION DISCLOSURE
CITATION IN AN APPLICATION**

June 15, 2004
(Use several sheets if necessary)

ATTORNEY DOCKET NO.
2629.1003-009

APPLICATION NO.
10/731,522

FIRST NAMED INVENTOR
Sudhir V. Shah

FILING DATE
December 9, 2003

EXAMINER
Randall O. Winston

CONFIRMATION NO.
3719


GROUP
1654

U.S. PATENT & TRADEMARK OFFICE
JUN 17 2004

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<input checked="" type="checkbox"/>	AE	5,091,180	02-25-92	Walker et al.
<input checked="" type="checkbox"/>	AF	6,206,849 B1	03-27-2001	Martin et al.
<input checked="" type="checkbox"/>	AG	6,383,817 B2	05-07-2002	Schwartz
<input checked="" type="checkbox"/>	AH	6,589,966 B1	07-08-2003	Torti et al.
<input checked="" type="checkbox"/>	AI	6,706,287 B2	03-16-2004	Ranganathan et al.

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
<input checked="" type="checkbox"/>	AP	WO 00/54784	09-21-2000	Aripkhodzhaeva	<input type="checkbox"/> <input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	AQ	JP 05000949 A	01-08-1993	Santen Pharmaceuticals Co., Ltd Dai Ichi Seiyaku Co., Ltd.	<input checked="" type="checkbox"/> (Abstract) <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<input checked="" type="checkbox"/>	AS4	Walker, P.D., et al., "Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats," <i>J Clin Invest</i> 81:334-341 (1988).
<input checked="" type="checkbox"/>	AT4	Shah, S.V., et al., "Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure," <i>Am J Physiol</i> 255, (Renal Fluid Electrolyte Physiol. 24):F438-F443 (1988).
<input checked="" type="checkbox"/>	AU4	Baliga, R., et al., "Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys," <i>Biochem J</i> 291(3):901-905 (1993).
<input checked="" type="checkbox"/>	AV4	Kontoghiorghe, G.J., et al., "Studies of Aluminium Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one," <i>Arzneim-Forsch/Drug Res.</i> 44(1):522-526 (1994).
<input checked="" type="checkbox"/>	AW4	Baliga, R., et al., "Oxidant Mechanisms in Toxic Acute Renal Failure," <i>Drug Metabolism Reviews</i> 31(4):971-991 (1999).
<input checked="" type="checkbox"/>	AX4	Walker, P.D., et al., "Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria," <i>Am J Physiol</i> 253:C495-C499 (1987).
<input checked="" type="checkbox"/>	AY4	Walker, P.D., et al., "Hydrogen Peroxide Cytotoxicity in LLC-PK ₁ Cells: A Role for Iron," <i>Kidney Int</i> 40:891-898 (1991).


EXAMINER 

DATE CONSIDERED 01/13/2005

@PFDsktop\ ODMA\MHODMA\HBSR05\iManage\472022\1

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION June 15, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-009		APPLICATION NO. 10/731,522	
	FIRST NAMED INVENTOR Sudhir V. Shah		FILING DATE December 9, 2003	
	EXAMINER Randall O. Winston		CONFIRMATION NO. 3719	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
W	AZ4	Abul-Ezz, S.R., et al., "Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure," <i>Proc Natl Acad Sci</i> 88:9833-9837 (1991).
W	AR5	Ueda, N., et al., "Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria," <i>Am J Physiol</i> 265(3 Pt. 2):F435-F439 (1993).
F	AS5	Baliga, R., et al., "Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure," <i>Kidney Int</i> 49:362-369 (1996).
V	AT5	Baliga, R., et al., "Role of Cytochrome P-450 as a Source of Catalytic Iron in Cisplatin-Induced Nephrotoxicity," <i>Kidney Int</i> 54:1562-1569 (1998).
V	AU5	Hanss, B.G., et al., "The Iron Chelator Deferoxamine Prevents Contrast Media Induced Acute Renal Failure in the Rabbit." Presented at the American Society of Nephrology, 23 rd Annual Meeting, <i>JASN</i> 1(4):612 (1990) (abstract).
F	AV5	Baliga, R., et al., "Role of Iron in Cisplatin-Induced Acute Renal Failure in Rats," <i>J Am Soc Nephrol</i> 7(9):1822 (1996) (abstract).
V	AW5	Fernández-Real, J.M., et al., "Cross-Talk Between Iron Metabolism and Diabetes," <i>Diabetes</i> , 51:2348-2354, 2002
V	AX5	Nitenberg, A., et al., "Coronary Microvascular Adaptation to Myocardial Metabolic Demand Can Be Restored by Inhibition of Iron-Catalyzed Formation of Oxygen Free Radicals in Type 2 Diabetic Patients," <i>Diabetes</i> , 51:813-818, 2002

EXAMINER 	DATE CONSIDERED 01/13/2005
---	-------------------------------

@PFDsktop\ODMA\MHODMA\HBSR05\iManage\472022;1

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-009		DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah			
	FILING DATE		CONFIRMATION NO.	GROUP 1654

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
<i>dw</i>	AA	5,047,421	Sep 10, 1991	Green
<i>dw</i>	AB	5,721,209	Feb 24, 1998	Horwitz <i>et al.</i>
<i>dw</i>	AC	5,811,127	Sep 22, 1998	Milstein <i>et al.</i>
<i>dw</i>	AD	4,684,482	Aug 4, 1987	Green
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			














EXAMINER <i>[Signature]</i>	DATE CONSIDERED 01/13/2005
--------------------------------	-------------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-009	DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah		
	FILING DATE	CONFIRMATION NO.	GROUP 1654

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
<i>W</i>	AL	WO 94/01770 A	20 Jan 94	PCT	X	
<i>N</i>	AM	DE 40 08 323 A	19 Sept 91	Germany	X	
<i>N</i>	AN	WO 00 13706 A	16 Mar 00	PCT (English)		
<i>N</i>	AO	WO 91 07956 A	13 June 91	PCT		
	AP					
	AQ					
	AL2					
	AM2					
	AN2					
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					
	AL5					
	AM5					

EXAMINER <i>Kuldev Ober</i>	DATE CONSIDERED <i>01/13/2003</i>
---------------------------------------	---

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-009	DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah		
	FILING DATE	CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AR	Sumboonnanda, A., <i>et al.</i> , "Renal tubular function in β -thalassemia", <i>Pediatr Nephrol</i> , 12:280-283.
	AS	Ong-ajyooth, L., <i>et al.</i> , "Renal Function in Adult Beta-Thalassemia/Hb E Disease", <i>Nephron</i> , 78:156-161 (1998).
	AT	Guasch, A., <i>et al.</i> , "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", <i>J Am Soc Nephrol</i> , 10:1014-1019 (1999).
	AU	Loebstein, R., <i>et al.</i> , "Diabetic Nephropathy in Hypertransfused Patients with β -Thalassemia", <i>Diabetes Care</i> , 21(8):1306-1309 (1998).
	AV	Ongajyooth, L., <i>et al.</i> , "Glomerulonephritis in β -thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).
	AW	Aoki, R.Y., <i>et al.</i> , "Microalbuminuria in Sickle Cell Disease", <i>Brazilian J Med Biol Res</i> , 23:1103-1106 (1990).
	AX	Katopodis, K.P., <i>et al.</i> , "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", <i>Journal of Nephrology</i> , 10(3):163-167 (1997).
	AY	Pham, P.-T.T., <i>et al.</i> , "Renal abnormalities in sickle cell disease", <i>Kidney International</i> , 57:1-8 (2000).
	AZ	Kontoghiorghe, G.J., <i>et al.</i> , "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", <i>Inorganica Chimica Acta.</i> , 136:L11-L12 (1987).
	AR2	Falk, R.J., <i>et al.</i> , "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme", <i>The New England Journal of Medicine</i> , 326(14):910-915 (1992).
	AS2	Guasch, A., <i>et al.</i> , "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", <i>Kidney International</i> , 51:826-833 (1997).
	AT2	Cianciulli, P., <i>et al.</i> , "Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy", <i>Kidney International</i> , 46:467-470 (1994).
	AU2	Ueda, N., <i>et al.</i> , "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", <i>Kidney International</i> , 49:370-373 (1996).

EXAMINER 	DATE CONSIDERED 01/13/2003
---	-------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-009		DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah			
	FILING DATE		CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AV2	~	Savill, J., <i>et al.</i> , "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 nd ed., pages 404-439, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
AW2	~	Ueda, N., <i>et al.</i> , "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", <i>Kidney: A Current Survey of World Literature</i> , 6:143-146 (1997).
AX2	~	Boyce, N.W., <i>et al.</i> , "Hydroxyl radical mediation of immune renal injury by desferrioxamine", <i>Kidney International</i> , 30:813-817 (1986).
AY2	~	Baliga, R., <i>et al.</i> , "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", <i>J Am Soc Nephrol</i> , 7(8):1183-1188 (1996).
AZ2	~	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).
AR3	~	Thakur, V., <i>et al.</i> , "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", <i>Kidney International</i> , 34:494-499 (1988).
AS3	~	Nankivell, B.J., <i>et al.</i> , "The Role of Tubular Iron Accumulation in the Remnant Kidney", <i>J Am Soc Nephrol</i> , 4(8):1598-1607 (1994).
AT3	~	Alfrey, A.C., <i>et al.</i> , "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", <i>Kidney International</i> , 36:753-759 (1989).
AU3	~	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 nd ed., pages 1749-1788, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
AV3	~	Howard R.L., <i>et al.</i> , "Urinary albumin, transferrin and iron excretion in diabetic patients", <i>International Society of Nephrology</i> , 40:923-926 (1991).
AW3	~	Olivieri, N.F., <i>et al.</i> , "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", <i>The New England Journal of Medicine</i> , 918-922 (1995).
AX3	~	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", <i>American Journal of Physiology</i> , 263(4):F637-F641 (1992).
AY3	~	Wu, Z-L., <i>et al.</i> , "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," <i>Renal Failure</i> 16(4):471-480 (1994).

EXAMINER 	DATE CONSIDERED 01/13/2005
---	-------------------------------

(Use several sheets if necessary)

**GROUP
1654**

[illegible]

EXAMINER

DATE CONSIDERED